Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo

 

Unsupported browser: Your browser does not meet modern web standards. See how it scores »

{ action.text }

“I think [the RainDance technology] holds lots of promise in a clinical setting,” says Hegde, who has been working with the technology for the last two years. But she also notes its cost. “The machine is very expensive,” she says, in the range of $200,000 to $250,000.

RainDance’s microdroplet technology is just one of a number of methods under development for selecting relevant genes within the genome. The Emory lab, for example, is also working with a technology from Fluidigm, another microfluidics company. It remains to be seen which will prove most effective in different situations.

One market that RainDance aims to dominate is cancer diagnostics, such as analyzing tumors for specific mutations that make them more likely to respond to certain drugs. Analyzing cancer DNA presents a unique challenge; the technology must be able to detect mutations in the tumor, which may occur in only a small subset of cells. Typical amplification methods expand both normal and cancerous pieces of DNA together, meaning the cancer mutation can get lost. One advantage of RainDance’s droplet technology is that it amplifies only one piece of DNA per droplet.

Foundation Medicine’s Borisy says the company will likely explore RainDance’s technology when developing its cancer genetic test. However, he cautions that cancer diagnostics need to be able to accurately amplify DNA from a very small sample. “For routine oncology, you need to be able to work from 100 nanograms or less,” he says.

RainDance is also working on a number of other applications, such as analysis of single cells, which could be used for drug toxicity testing. For example, drug companies could encapsulate single cells into droplets, expose the cells to experimental compounds, and then add fluorescent tags designed to bind to markers of cell death.

2 comments. Share your thoughts »

Credit: RainDance

Tagged: Biomedicine, sequencing, diagnostics, genetic testing, microfluidics

Reprints and Permissions | Send feedback to the editor

From the Archives

Close

Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me